October 6, 2019
LabCentral, the Cambridge-based research laboratory, is set to open a new incubator focused on “scale-up biomanufacturing” in 2021.
The initiative is fueled by investment from Astellas Pharma, a 14-year-old pharmaceutical company based in Tokyo, and a grant from the Massachusetts Life Sciences Center.
Astellas will put $12.5 million into sponsoring the new incubator, a 100,000-sq.-ft. facility set to feature a core lab space where companies can conduct process development studies and a non-GMP pilot plant, according to a press release. The incubator will be officially known as “LabCentral 238″—a riff on its location at 238 Main St. in Cambridge—and is expected to open in fall 2021.
Read Complete Article